Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-40. (Cancelled).

Claim 41. (Currently amended) An anti-adhesion patch made by the process of mixing a Type I collagen molecules with human fibroblast cells that adapt and organize the Type I collagen molecules into monocellular tissue equivalents and whereby the cells organize randomly the Type I collagen molecules into the patch in vitro.

Claim 42. (Previously presented) The anti-adhesion patch of claim 41, further comprising type III collagen.

Claim 43. (Previously presented) The anti-adhesion patch of claim 41, further comprising at least one of elastin, interstitial collagens, collagen type III, V and IX, glycoproteins or proteoglycans.

Claim 44. (Previously presented) The anti-adhesion patch of claim 41, wherein the Type I collagen molecule is from a natural source or a recombinant source.

Claim 45. (Previously presented) The anti-adhesion patch of claim 41, wherein the cells are engineered cells.

Claim 46. (Previously presented) The anti-adhesion patch of claim 41, wherein the cells are dermal fibroblasts or vascular smooth muscle cell.

Claim 47. (Previously presented) The anti-adhesion patch of claim 41, further comprising the step of removing the cells from the patch once the patch has been formed.

Claim 48. (Previously presented) The anti-adhesion patch of claim 41, wherein the patch further comprises a fibrin glue that is disposed on the patch.

Claim 49. (Previously presented) The anti-adhesion patch of claim 41, wherein patch is adapted for use in the thoracic cavity, ophthalmic system, orthopedic system, and the central nervous system.

Claim 50. (Previously presented) The anti-adhesion patch of claim 41, further comprising the addition of one or more growth factors selected from fibroblast growth factor (FGF), epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factor beta (TGF β), transferrin, insulin and serum.

Claim 51. (Currently amended) An anti-adhesion patch made by the process of mixing Type I collagen molecules with human fibroblasts capable of organizing Type I collagen molecules in situ and in vitro under cell culture conditions for 14 days or less, whereby the cells organize <u>randomly</u> the Type I collagen molecule into the patch.

The anti-adhesion patch of claim 51, further comprising Claim 52. (Previously presented) human type III collagen.

Claim 53. (Previously presented) The anti-adhesion patch of claim 51, further comprising at least one of elastin, interstitial collagens, collagen type III, V and IX, glycoproteins or proteoglycans.

Claim 54. (Previously presented) The anti-adhesion patch of claim 51, wherein the Type I collagen molecule is from a natural source or a recombinant source.

Claim 55. (Previously presented) The anti-adhesion patch of claim 51, wherein the cells are engineered cells.

Claim 56. (Previously presented) The anti-adhesion patch of claim 51, wherein the cells are dermal fibroblasts.

Claim 57. (Previously presented) The anti-adhesion patch of claim 51, further comprising the step of removing the cells from the patch once the patch has been formed.

Appl. No. 10/628,787

Amdt dated: October 24, 2008

Reply to Office action of April 24, 2008

Claim 58. (Previously presented) The anti-adhesion patch of claim 51, wherein the patch

further comprises a fibrin glue that is disposed on the patch.

Claim 59. (Previously presented) The anti-adhesion patch of claim 51, wherein patch is

adapted for use in the thoracic cavity, ophthalmic system, orthopedic system, and the central

nervous system.

Claim 60. (Previously presented) The anti-adhesion patch of claim 51, wherein patch is

adapted for attach to the pericardium and prevents adhesions between the epicardium and the

pericardium.